|
1. |
Comparison of HTLV-I Basal Transcription and Expression of CREB/ATF-1/CREM Family Members in Peripheral Blood Mononuclear Cells and Jurkat T Cells |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 1-10
Garret Newbound,
John O'Rourke,
Nathaniel Collins,
James DeWille,
Michael Lairmore,
Preview
|
|
摘要:
HTLV-I is the etiologic agent of adult T-cell leukemia/lymphoma and is associated with tropical spastic paraparesis/HTLV-I-associated myelopathy. Following integration into the host cell genome, HTLV-I replication is regulated by both host and viral mechanisms that control transcription. Low levels of viral transcription (basal transcription) occur before expression of the virally encoded Tax protein (Tax-mediated transcription). Members of the cyclic adenosine monophosphate (cAMP) response element binding (CREB)/activating transcription factor 1 (ATF-1) family of transcription factors bind three 21-bp repeats (Tax-responsive element-1, or TRE-1) within the viral promoter and are important for basal and Tax-mediated transcription. Using mitogen stimulated and quiescent peripheral blood mononuclear cells (PBMC) and Jurkat cells, we compared differences in basal transcription and amounts and binding of transcription factors with TRE-1. We demonstrate that amounts of transcriptionally active phosphorylated CREB protein (P-CREB) differ between activated PBMC and Jurkat cells. Following stimulation, P-CREB levels remain elevated in PBMC for up to 24 hours whereas CREB is dephosphorylated in Jurkat cells within 4 hours following stimulation. The differences in P-CREB levels between PBMC and Jurkat cells were directly correlated with basal transcription of HTLV-I in the two cell types. Using electrophoretic mobility shift assays, we determined that the pattern of band migration differed between the two cell types. These data demonstrate that PBMC differentially regulate basal HTLV-I transcription compared with Jurkat T cells, and this differential regulation is due, in part to differential phosphorylation and binding of CREB/ATF-1 to TRE-1 in the HTLV-I promoter. We demonstrate the utility of using primary lymphocyte models to study HTLV-I transcription in the context of cell signaling and suggest that activated PBMC maintain elevated levels of P-CREB, which promote basal HTLV-I transcription and enhance viral persistence in vivo.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
2. |
A Randomized, Double-Blind Trial on the Use of a Triple Combination Including Nevirapine, a Nonnucleoside Reverse Transcriptase HIV Inhibitor, in Antiretroviral-Naive Patients With Advanced Disease |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 11-19
M. Floridia,
R. Bucciardini,
D. Ricciardulli,
V. Fragola,
M. Pirillo,
L. Weimer,
C. Tomino,
G. Giannini,
C. Galluzzo,
M. Andreotti,
A. Cargnel,
F. Alberici,
B. De Rienzo,
F. Leoncini,
F. Fiaccadori,
D. Francisci,
W. Grillone,
L. Ortona,
M. Piazza,
A. Scalzini,
E. Nigra,
F. Tumietto,
S. Vella,
Preview
|
|
摘要:
The immunologic and virologic activity of nevirapine in combination with two nucleosides (zidovudine [ZDV] and didanosine [ddI]) was evaluated in antiretroviral-naive patients with a CD4 count <200/mm3or clinical AIDS. In all, 68 patients were enrolled in a 48-week double-blind, placebo-controlled trial. A group of 32 patients received ZDV + ddI + nevirapine, and 36 patients received ZDV + ddI. Primary efficacy parameters were the activity on HIV-1 RNA and on peripheral blood CD4+cells, with differences between groups analyzed by the Wilcoxon's nonparametric two-sample test. Baseline RNA was high in both treatment groups (median values, 5.8 and 5.7 log10). RNA and CD4 responses were significantly higher with the triple combination (median RNA reductions, 2.69 versus 1.05 log10at 24 weeks and 1.97 versus 1.20 log10at 48 weeks; median CD4 increases, 81 versus 64 cells/mm3at 24 weeks and 101 versus 27 cells/mm3at 48 weeks). This study demonstrates that a triple combination of ZDV + ddI + nevirapine used as first-line regimen in antiretroviral-naive patients can induce sustained virologic and immunologic response in patients with low CD4 count or a previous diagnosis of AIDS.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
3. |
Concomitant Therapy With Subcutaneous Interleukin-2 and Zidovudine Plus Didanosine in Patients With Early Stage HIV Infection |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 20-27
Cecilia Simonelli,
Stefania Zanussi,
Simonetta Sandri,
Manola Comar,
Antonio Lucenti,
Renato Talamini,
Maria Bortolin,
Mauro Giacca,
Paolo De Paoli,
Umberto Tirelli,
Preview
|
|
摘要:
A phase II study was performed to evaluate the feasibility and activity of subcutaneous (SC) interleukin-2 (IL-2) administration plus zidovudine (ZDV) and didanosine (ddI) in patients with early stage HIV infection. Between October 1995 and October 1996, 12 patients completed 6 cycles of the following scheduled therapy: ZDV plus ddI and SC self-administration of 6 mIU of IL-2 at days 1 to 5 and 8 to 12 of a 28-day cycle for a total of 6 cycles (24 weeks). After 6 cycles, patients received only ZDV plus ddI and they were observed up for an additional 24 weeks. Our schedule was well tolerated as an outpatient regimen and led to a significant elevation in CD4 count, which lasted for 24 weeks after the end of IL-2 therapy. Moreover, CD4/CD25, as well as CD4/CD45RO and CD4/CD45RA, cell levels were significantly increased at the end of the therapy and remained significantly elevated after 24 weeks. During the 6 cycles, HIV-associated viremia was significantly decreased and, accordingly, we observed a significant decline of proviral DNA in peripheral blood mononuclear cells (PBMCs). During follow-up, 10 of 12 treated patients continued to show levels of HIV-related viremia <500 copies/ml. Our results demonstrated that IL-2 and ZDV plus ddI is a well tolerated and effective therapy for patients with HIV in early stages of the disease.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
4. |
Protease Inhibitor-Based Therapy Is Associated With Decreased HIV-Related Health Care Costs in Men Treated at a Veterans Administration Hospital |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 28-33
Philip Keiser,
Mary Kvanli,
Dianna Turner,
Joan Reisch,
James Smith,
Naiel Nassar,
Clark Gregg,
Daniel Skiest,
Preview
|
|
摘要:
Background:Protease inhibitor (PI) therapy for HIV infection is associated with decreased rates of opportunistic infections and death. Statistical models predict that decreased complications will be associated with decreased hospitalization costs. A recent report suggested that the decrease in the HIV hospitalization costs were offset by increases in demand for outpatient services. We performed a study of hospital use and HIV-associated health care costs in our center to determine the following: whether PI therapy is associated with decreased inpatient use; whether PI therapy is associated with decreased outpatient use and costs; whether decreased HIV health care costs are associated with increased use of nucleoside analogues.Methods:The Dallas Veteran Affairs Medical Center provides comprehensive inpatient and outpatient HIV care and thus can evaluate the relation between inpatient and outpatient costs. The mean monthly number of hospital days, Infectious Diseases clinic visits, emergency department visits, other outpatient clinic visits, inpatient costs, outpatient costs, and PI costs were determined from January 1, 1995 through July 31, 1997. This time period was then divided into three intervals. Comparisons of PI use and HIV-related health care costs were during the three intervals was performed using analysis of variance (ANOVA). Significant differences between the baseline characteristics were further analyzed through multiple linear regression.Results:A decrease in hospital days, and all outpatient visits including emergency visits, and HIV clinic visits was determined. No difference was found in the rate of use of other outpatient services. The per patient costs of HIV care decreased from a monthly average of $1905 U.S. in the first interval to $1122 U.S. in the last interval (p< .01). Linear regression demonstrated an inverse relation between PI use and total HIV costs (B = −0.67,p= .00, adjusted R2= 0.52) but no relation between nucleoside use, stage of disease or financial class.Conclusions:PI therapy is associated with decreased hospital days and use of outpatient services. Total patient costs decreased, but a concomitant rise in outpatient costs took place. This increase was primarily a result of increased costs of acquiring PI. Increases in the number of nucleoside agents prescribed were not associated with decreased costs.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
5. |
Effect of Antiviral Drugs Used to Treat Cytomegalovirus End-Organ Disease on Subsequent Course of Previously Diagnosed Kaposi's Sarcoma in Patients With AIDS |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 34-38
Robert Robles,
Denise Lugo,
Lauren Gee,
Mark Jacobson,
Preview
|
|
摘要:
Objective:To evaluate the association of ganciclovir (GCV) and foscarnet (PFA) therapy with the outcome of previously diagnosed Kaposi's sarcoma (KS) after initiating antiviral therapy for cytomegalovirus (CMV) end-organ disease.Design:Retrospective study.Methods:KS progression was defined as a clinically obvious increase in size of baseline cutaneous or mucosal lesions, a new diagnosis of visceral KS, or initiation of a new systemic antineoplastic regimen or radiation therapy to treat KS. Multivariate analyses of risk of KS progression were calculated for prior duration of KS before initiating CMV treatment, treatment with PFA or GCV, number of weeks treated with PFA or GCV, absolute CD4 lymphocyte count at time of CMV-related disease diagnosis, diagnosis of KS prior to 1991, visceral KS, prior systemic chemotherapy, and prior radiation therapy.Results:Among 66 patients who received ⩾14 days PFA (N= 20) or only GCV (N= 46), median time to progression of KS was 211 days (95% confidence interval [CI], 46-578) for patients who received PFA versus 22 days (95% CI, 15-41) for those who received only GCV (p< .001). In the stepwise multivariate analysis, only prior visceral KS (rate ratio [RR] = 2.80; 95% CI, 1.07-7.35) and foscarnet therapy (RR = 0.24; 95% CI, 0.11-0.53) were significantly associated with risk of KS progression.Conclusion:PFA may be an effective therapy for AIDS-related KS; prospective trials are indicated.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
6. |
Failure to Detect Nelfinavir in the Cerebrospinal Fluid of HIV-1-Infected Patients With and Without AIDS Dementia Complex |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 39-43
Francesca Aweeka,
Anura Jayewardene,
Silvija Staprans,
S. Bellibas,
Brian Kearney,
Patricia Lizak,
Tatjana Novakovic-Agopian,
Richard Price,
Preview
|
|
摘要:
Objective:To assess the penetration of the HIV-1 protease inhibitor, nelfinavir, into cerebrospinal fluid (CSF).Design:Nelfinavir, a commonly used HIV-1 protease inhibitor (PI), is highly effective for reducing plasma viral load. It is deployed clinically in combination with other antiretroviral agents, including nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs). Despite its potency based on plasma HIV-1 RNA results, its effectiveness in reducing HIV-1 RNA levels (i.e., viral load) in the central nervous system (CNS) is less certain. We sampled the CSF as a surrogate for brain because this fluid also is separated from the blood by a barrier to free diffusion, the blood-CSF barrier (BCB), which shares properties with the blood-brain barrier (BBB). These studies of nelfinavir CSF pharmacokinetics exploited the multiple CSF samples derived from individual study subjects who were enrolled in studies the primary objective of which was to compare viral kinetics in CSF and blood in response to antiviral therapy.Methods:Six study subjects, four with and two without AIDS dementia complex, underwent multiple lumbar punctures (LP). Intervals of CSF sampling after drug dosing were varied (from 0.48 hours to 10.3 hours after nelfinavir administration) to quantitate nelfinavir concentrations throughout the steady-state dosing interval. In four study subjects, CSF sampling was accompanied by assessment of nelfinavir levels in plasma before and after LP, whereas in the other two subjects, a single plasma sample was obtained before or after the LP. In total, 25 CSF samples were analyzed. Nelfinavir concentrations in CSF and plasma were determined using an high-performance liquid chromatography (HPLC) method with a limit of quantitation of 25 and 50 ng/ml, respectively.Results:Plasma concentrations before and after LP averaged 2420 ± 1365 ng/ml and 2528 ± 1132 ng/ml, respectively. Nelfinavir was not detected in any of the CSF samples and levels >25 ng/ml were not present in the CSF. Thus, standard therapy with nelfinavir does not result in CSF drug concentrations at or exceeding the IC95 level for most HIV-1 isolates. However, study subjects with high CSF viral loads experienced a marked reduction in the context of the combination-drug regimen including nelfinavir with two subjects showing a comparable CSF response with that in plasma.Conclusions:Nelfinavir does not appreciably penetrate into the CSF. The clinical importance of this observation is not certain, in that in four study subjects who initiated nelfinavir in combination with other antiretroviral therapy, a comparable degree of viral suppression was obtained in both the CSF and the blood when sampled 4 weeks or later after initiating therapy.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
7. |
Short-Term Effects of Large-Dose Vitamin A Supplementation on Viral Load and Immune Response in HIV-Infected Women |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 44-51
Jean Humphrey,
Thomas Quinn,
David Fine,
Howard Lederman,
Sedighe Yamini-Roodsari,
Lee Wu,
Suzen Moeller,
Andrea Ruff,
Preview
|
|
摘要:
Vitamin A supplementation has been suggested for treatment and prevention of HIV infection. However, some in vitro data indicate that vitamin A may activate HIV. Randomly, 40 HIV-seropositive women of reproductive age were allocated to receive a single oral dose of 9900 μmol (300,000 IU) vitamin A or placebo. Plasma HIV-1 RNA concentration, total lymphocytes, selected lymphocyte subsets and activation markers, and in vitro lymphocyte proliferation to phytohemagglutinin (PHA) andCandidawere measured before dosing and at various time points over an 8-week follow-up period. No differences were found between treatment groups in the frequency of signs or symptoms of acute vitamin A toxicity, nor were differences evident in any lymphocyte subset or activation marker at any time during follow-up. Mean and median viral load concentration at each time point and change in viral load from baseline to each follow-up point did not differ between treatment groups. No difference was measured between treatment groups in the proportion of women who responded to PHA or Candida. This study provides no evidence that high dose vitamin A supplementation of HIV-infected women is associated with significant clinical or immunologic adverse effects.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
8. |
HIV Infection and Disturbances of Vaginal Flora During Pregnancy |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 52-59
Taha Taha,
Ronald Gray,
Newton Kumwenda,
Donald Hoover,
Laban Mtimavalye,
George Liomba,
John Chiphangwi,
Gina Dallabetta,
Paolo Miotti,
Preview
|
|
摘要:
Disturbances of vaginal flora are common among women of reproductive age. In areas of sub-Saharan Africa where the prevalence of HIV is high, the frequency of bacterial vaginosis (BV) is also high. In this study, we assessed the association of BV and other disturbances of vaginal flora with prevalent HIV infection in two cross-sectional studies among pregnant women in urban Malawi. The prevalence of HIV-1 was 23% in 1990 and 30% in 1993. Overall, 30% of the women had BV, 59% had mild or moderate disturbance of vaginal flora, and only 11% had normal vaginal flora. Increasing prevalence of HIV was significantly associated with increasing severity of disturbance of vaginal flora (p< .00001, χ2trend test). This trend of increased prevalence persisted after controlling for concurrent sexually transmitted diseases (STDs), sexual activity, and socioeconomic factors. After multivariate adjustment for potential confounders, the odds ratio for the association of BV with prevalent HIV infection was 3.0 (95% confidence interval [CI], 2.4-3.8), that of moderate vaginal disturbance with HIV infection was 2.2 (95% CI, 1.7-2.8), and that of mild vaginal disturbance with HIV infection was 1.6 (95% CI, 1.3-2.1). Among women with BV, HIV infection was higher among younger women than older, implying more recent infection. Although these studies were cross-sectional, our data suggest that BV could be associated with increased susceptibility to HIV infection.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
9. |
HIV-1 Subtypes Among Blood Donors From Rio de Janeiro, Brazil |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 60-66
Amilcar Tanuri,
Priscilla Swanson,
Sushil Devare,
Oscar Berro,
Ana Savedra,
Luciana Costa,
Jose Telles,
Rodrigo Brindeiro,
Charles Schable,
Danuta Pieniazek,
Mark Rayfield,
Preview
|
|
摘要:
The prevalence of HIV infection in Brazil is one of the highest in the world. In addition, transfusion-transmitted HIV accounts for 2.3% of all AIDS cases in Brazil. The objective of this study was to evaluate genetic diversity and distribution of HIV-1 strains circulating in the blood-donor population. We characterized 43 seropositive blood units collected from volunteer blood donors residing throughout Rio de Janeiro, Brazil. Viral RNA was extracted from plasma, reverse transcribed, and amplified by nested polymerase chain reaction (PCR) using HIV group M degenerate primers. Genetic heterogeneity was evaluated by direct automated cycle sequencing of the following gene fragments:gagp24 (399 bp),envC2V3 (345 bp), andenvgp41 (369 bp). Phylogenetic analysis reflected the complexity of the Brazilian HIV epidemic: the majority of specimens, 33 of 43 (76.7%) were subtype B, and 6 of 43 (14%) were subtype F. The remaining 4 samples (9.3%) involved potential mosaic viruses of subtypes B and F or B and D. This survey is the first to document HIV-1 genetic variation in the Brazilian blood-donor population.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
10. |
Risk Behavior and HIV Infection Among New Drug Injectors in the Era of AIDS in New York City |
|
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,
Volume 20,
Issue 1,
1999,
Page 67-72
Don Des Jarlais,
Samuel Friedman,
Theresa Perlis,
Tim Chapman,
Jo Sotheran,
Denise Paone,
Edgar Monterroso,
Alan Neaigus,
Preview
|
|
摘要:
Objective:To examine HIV risk behavior and HIV infection among new initiates into illicit drug injection in New York City.Design and Methods:Cross-sectional surveys of injecting drug users (IDUs) recruited from a large detoxification treatment program (n= 2489) and a street store-front research site (n= 2630) in New York City from 1990 through 1996. Interviews covering demographics, drug use history, and HIV risk behavior were administered; serum samples were collected for HIV testing. Subjects were categorized into two groups of newer injectors: very recent initiates (just began injecting through 3 years) and recent initiates (injecting 4-6 years); and long-term injectors (injecting ⩾7 years).Results:954 of 5119 (19%) of the study subjects were newer injectors, essentially all of whom had begun injecting after knowledge about AIDS was widespread among IDUs in the city. New injectors were more likely to be female and white than long-term injectors, and new injectors were more likely to have begun injecting at an older age (median age at first injection for very recent initiates, 27 years; median age at first injection for recent initiates, 25 years; compared with median age at first injection for long-term injectors, 17 years). The newer injectors generally matched the long-term injectors in frequencies of HIV risk behavior; no significant differences were found among these groups on four measures of injection risk behavior. HIV infection was substantial among the newer injectors: HIV prevalence was 11% among the very recent initiates and 18% among the recent initiates. Among the new injectors, African Americans, Hispanics, females, and men who engaged in male-male sex were more likely to be infected.Conclusions:The new injectors appear to have adopted the reduced risk injection practices of long-term injectors in the city. HIV infection among new injectors, however, must still be considered a considerable public health problem in New York City.
ISSN:1077-9450
出版商:OVID
年代:1999
数据来源: OVID
|
|